Peter George Joins Board Of ErgoMed As Non-Executive Director
Guildford, UK – 21 May 2014: Ergomed, a UK-based drug development services company, today announces the appointment of Peter George to its Board as Non-Executive Director.
Peter George has over 20 years' experience in the pharmaceutical services industry and is currently Chief Executive Officer of Clinigen Group plc (AIM: CLIN), the global specialty pharmaceuticals and pharmaceutical services business. Prior to Clinigen, he was CEO at Penn Pharma, having led a £67M management company buy-out (2007). Before this, Peter was executive VP for Wolters Kluwer Health with responsibility for Europe and Asia Pacific regions. Peter has also held roles as the Chief Operating Officer of Unilabs Clinical Trials International Limited; head of Clinical Pathology NHS and as Director of PharmaPatents Global.
Rolf Stahel, Chairman of Ergomed, commented: "We are delighted that Peter has joined Ergomed as Non-Executive Director. He has an excellent track record of building international pharmaceutical services businesses. His expertise and experience will be invaluable as we continue to grow and expand our services and co-development business."
Peter George, Chief Executive Officer of Clinigen, said: "I am very pleased to join the Board of Ergomed. The company has shown strong growth since its inception 15 years ago and I have been very impressed with the expertise and quality within the company. I believe Ergomed has great potential and look forward to being a part of the team."
About Ergomed
Ergomed is a fast growing, profitable UK-based drug development services company. It operates in over 40 countries across five continents. Since its formation in 1997, Ergomed has been providing expertise in clinical development and trial management for over 100 clients ranging from top 10 pharmaceutical companies to small and mid-sized drug development companies. Ergomed has a wide therapeutic focus, but has particular expertise in oncology, neurology and immunology and the development of orphan drugs. Ergomed believes its approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed and the physicians involved in clinical trials.
As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies which share the risks and rewards of drug development. Ergomed leverages its expertise and services in return for carried interest in the drugs under development. For further information, visit: http://ergomedgroup.com
For media and all other enquiries, please contact:
Hume Brophy
Mary Clark, Supriya Mathur, Hollie Vile
Tel: + 44 203 440 5654